Arrowhead Pharmaceuticals Announces $200M Offering of Common Stock and Pre-Funded Warrants

summarizeSummary

Arrowhead Pharmaceuticals is conducting a $200 million offering of common stock and pre-funded warrants to bolster its financial position and extend its operational runway into fiscal year 2029.

check_boxKey Events · Financing and Capital Events · ARWR

• Capital Raise Announced

  Arrowhead Pharmaceuticals is offering $200 million in common stock and pre-funded warrants.

• Dilution Expected

  The offering is expected to result in immediate and substantial dilution for new investors.

• Extended Cash Runway

  Proceeds, combined with a concurrent convertible note offering, are projected to fund operations into fiscal year 2029.

• Use of Proceeds

  Funds will support general corporate purposes, including R&D, clinical trials, and potential prepayment of high-interest debt.

auto_awesomeAnalysis · ARWR · Life Sciences

This Free Writing Prospectus details a significant capital raise by Arrowhead Pharmaceuticals, involving $200 million in common stock and pre-funded warrants. While the offering will result in immediate and substantial dilution for existing shareholders, it is crucial for funding the company's general corporate purposes, including research and development, clinical trials, and commercialization efforts. The proceeds are also intended to potentially prepay loans under a high-interest credit facility, which would improve the company's balance sheet. Importantly, the company anticipates these funds, combined with a concurrent convertible note offering, will extend its cash runway into fiscal year 2029, providing critical stability for its long-term development and commercialization plans.